Checkpoint Inhibitor Trials

August 12, 2016 | by City of Hope

Checkpoint inhibitors allow for activation of the bodies' immune system against the cancer. A spectrum of tumor types have responded to this novel therapeutic approach.

For more information on a specific clinical trial, please call 626-218-1133. For a full listing of clinical trials, visit clinicaltrials.coh.org

  Checkpoint Inhibitor Trials
 
Learn more about
Dr. Herrera
Alex Herrera, M.D.
IRB 15041: A Multi-Center Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas.

Phase Ib
IRB 15467: Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies.

Phase I/II
IRB 15204:Study Evaluating Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma after Failure of Frontline Therapy.

Phase I/II
IRB 15137: Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma.
 
 
Learn more about
Dr. Zain
Jasmine Zain, M.D.
PHASE II
IRB 15332: A Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL).
 
 
Learn more about
Dr. Yuan
Yuan Yuan, M.D., Ph.D.
PHASE Ib/II
IRB 15232: An Open-Label, Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC).
 
 
Learn more about
Dr. Somlo
George Somlo, M.D.

IRB 15295: MK-3475 (pembrolizumab) in Combination with an Anthracycline or Anti-Estrogen Therapy in Patients with Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer .
 
 
Learn more about
Dr. Fakih
Marwan Fakih, M.D.
PHASE III
IRB 16120: Open-Label, Multicenter, Three-arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Vs. Regorafenib in Patients with Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma.
 
 
Learn more about
Dr. Pal
Sumanta Pal, M.D.
PHASE I
IRB 15256: Cabozantinib, nivolumab and ipilimumab in combination for advanced GU tumors.
 
 
Learn more about
Dr. Cristea
Mihaela Cristea, M.D.
PHASE I
IRB 13373: A Study of of a p53MVA Vaccine in Combination with Gemcitabine in Ovarian Cancer.
 
 
Learn more about
Dr. Chung
Vincent Chung, M.D.
PHASE I
IRB 15002: A Study of p53MVA Vaccine in Combination with Pembrolizumab.
 
  Upcoming CheckPoint Inhibitor Trials
 
Tanya Siddiqi, M.D.
Learn more about
Dr. Siddiqi
Tanya Siddiqi, M.D.
IRB 16059: Pembrolizumab with Dinaciclib.
 
 
Learn more about
Dr. Herrera
Alex Herrera, M.D.
IRB 16197: Two cohort study of nivolumab for primary CNS lymphoma .

IRB 16089: MEDI14736 with tremelimumab or AZD 9150.
 
 
Learn more about
Dr. Li
Daneng Li, M.D.
PHASE III
IRB 16040: A Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240).
 
 
Learn more about
Dr. Pal
Sumanta Pal, M.D.
PHASE II
IRB 16106: A Randomized, Double-blinded, study of Maintenance Pembrolizumab versus Placebo After First-line Chemotherapy in Patients with Metastatic Urothelial Cancer.
 
 
Learn more about
Dr. Yuan
Yuan Yuan, M.D., Ph.D.
PHASE II
IRB 16058: The Addition of MK-3475 (Pembrolizumab) to Letrozole and Palbociclib in Patients with Metastatic Estrogen Receptor Positive Breast Cancer Who Have Stable Disease But Are Not Responding to Letrozole and Palbociclib.
 
                                                           

 

Back To Top

Search Blogs